Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer
The various options for optimal chemotherapy are indicated depending on the patient's conditions during the diagnosis of mCRPC. Treatment with DCT at 2-week or even 1-week intervals appears to be well tolerated in men diagnosed with mCRPC and represents a useful option when the conventional triweekly regimen is not tolerated due to poor patient condition.
Authors
- Ja Hyeon Ku (ORCID: https://orcid.org/0000-0002-0391-2342)
- Hyeong Dong Yuk (ORCID: https://orcid.org/0000-0002-5874-9167)
- Chang Wook Jeong (ORCID: https://orcid.org/0000-0002-2200-5019)
- Cheol Kwak (ORCID: https://orcid.org/0000-0002-1987-2111)
- Bhumsuk Keam (ORCID: https://orcid.org/0000-0001-8196-4247)
- Miso Kim (ORCID: https://orcid.org/0000-0002-4064-4199)
Institutions
- Seoul National University (KR)
- New Generation University College (ET)
Publication Details
- Journal
- Prostate International
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1016/j.prnil.2024.09.002
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09